START criteria

START criteria (Start, Stop, Continue, Think) is a clinical decision-making tool designed for high-risk patients to optimize medication therapy. It systematically evaluates each patient's medication list to identify necessary additions, unnecessary medications, ongoing treatments, and medications requiring reassessment. In the context of enterprise risk management (ERM), it aligns with ISO 31000 principles for risk identification and ISO 14121 for medical device risk-adjusted-by-design. Unlike the Beers or STOPP criteria which focus on avoiding harm, START focuses on proactive therapeutic optimization. For pharmaceutical and medtech enterprises, this tool provides a structured methodology for post-market safety surveillance and product-use risk assessment, ensuring that therapeutic benefits outweigh potential harms as required by international regulatory bodies like the FDA and EMA.

Implementation follows a three-step methodology. Step 1: Risk Identification—Integrate START criteria into the product safety database to flag medications prone to misuse or omission. Step 2: Risk Analysis—Use ISO 14971 to quantify the severity and probability of adverse events associated with improper medication use. Step 3: Risk Treatment—Update product labeling,-instructions for use (IFU), or clinical guidance based on the findings. For example, a pharmaceutical company in Taiwan identifying a high rate of 'Start'-category risks in elderly patients must be able to demonstrate corrective and preventive action (CAPA) under the Pharmaceutical Safety Act. Successful implementation typically results in a 25-35% reduction in medication-related adverse events and a significant improvement in regulatory compliance scores during audits.

Taiwan enterprises face three primary challenges. First, regulatory knowledge gaps: Many companies lack the expertise to map clinical tools like START to ISO 31000 risk management frameworks. The solution is to invest in cross-functional training involving both clinical and compliance teams. Second, data-handling complexities: Using patient-specific medication data for risk-adjusted product-use analysis requires strict adherence to the Taiwan Personal Data Protection Act (第19條). Companies must implement privacy-preserving data-handling protocols before proceeding. Third, resource constraints: Small to medium enterprises (SMEs) often lack the budget for dedicated pharmacovigilance teams. The optimal approach is to be incremental: start with high-risk product categories, then scale up as the ROI from reduced adverse events and regulatory fines becomes evident. A 90-day implementation roadmap is recommended for initial compliance stabilization.

Winners Consulting Services Co., Ltd. specializes in START criteria implementation for Taiwan enterprises, delivering compliant management systems within 90 days. We have assisted over 100 companies in integrating clinical risk tools into their ERM frameworks. Free consultation: https://winners.com.tw/contact